Photobiomodulation therapy for dry age-related macular degeneration
Topic Status Complete
Age-related macular degeneration (AMD) is the leading cause of vision loss in people over 50 years old. Dry AMD affects around 80% of people with AMD and there are currently no established treatments. Photobiomodulation (PBM) therapy has been proposed as a treatment for dry AMD. PBM uses near infrared spectrum light to stimulate cells of the retina and delay cell death.
Summary
Health Technology Wales researchers searched for evidence on PBM therapy for dry AMD.
The HTW Assessment Group decided not to progress this topic further due to the lack of evidence of effectiveness at present.
Topic Exploration Report
TER467 09.2023
Access our guidance
Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it.
